Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP raptor resources limited

0.00%

20.5¢

What to expect if Pfizer's takeover fails, page-5

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 5 Last

Share
Profile

Follow
UrbanGazelle

65 Posts.

77

27/07/22

15:52

Post #: 62758278
Share

Originally posted by The 8th Wonder: ↑

I thought it would add value to HC readers to flesh out what Resapp may look like if the Pfizer transaction fails.

Prior to the Pfizer bid, Resapp traded for $0.09 per share. This is relevant because the pre-bid price generally becomes the new ceiling price when a transaction fails.

However, Resapp’s register is filled with arb funds that will immediately sell if the transaction does not proceed. So I’d expect the price to fall even further than $0.09. For the purposes of this exercise, let’s assume 12% of Resapp’s register is held by arb funds. On July 26th, 12% was held by nominees Citicorp, BNP Paribas, JP Morgan and HSBC (not including Fidelity).

Based on all of these shareholders rushing for the exit, I estimate that Resapp’s share price could fall to $0.05-0.07 in the event the transaction fails. It’s possible that it’s even worse (or better) than this, but this is my best guess.

Resapp would then find itself in the unfortunate situation of having to raise capital immediately at an incredibly inopportune time.

Resapp had $2.29m of cash on June 30 2022 and at the current run rate they’re burning about $3.4m a quarter. They’ll be out of money before September 2022 at this rate. So after the vote results are announced on the 19th of August they’ll have days ( I reiterate, days!) to raise money or else they’ll enter administration.

To get a capital raise away, new shares need to be offered at a discount. Tech and biotech businesses are heavily out of favour at the moment so it's a particularly unattractive time to raise capital. Larger discounts than normal are required at the moment. The poor results of Resapp’s data confirmation study doesn’t do them any favours either.

If we assume a 20% discount they’d raise at $0.04-0.056 per share. Resapp raised $5.8m at a 15% discount in April 2021, however, it’s a much more difficult time to be raising capital, so it's logical to expect a larger discount. I think 20% is a reasonable assumption but it's possible they’d need to offer an even bigger discount.

This means that if the transaction fails, shareholders could be sitting on a 51-65% loss from today’s price. The shares would need to rise by 265% to get back to the price offered by Pfizer.

I appreciate many shareholders have strong belief in Resapp’s technology. But the odds of Resapp being a good investment if this transaction fails are heavily against them. If you invest to make money, it makes sense to accept the deal.

Further, if you accept the deal and then use the $0.146 proceeds to buy a new investment, and let’s assume the new investment makes a 30% return, you’ll have 4.7x more money than if you hold Resapp and the deal fails and the share price heads to $0.04. Avoiding big losses is very important.

Expand

A few new HC Rap posters recently working overtime in the 11th hour to promote tk and the boards view of the scheme. Hummm…not suspicious. I am happy to hold for a few more years so short term movements post the no vote have no interest to me.

I also just had a call from CP in Melbourne asking how I will be voting. I said I’ve ‘already voted no’.

I get the impression they are scrambling because all indicators point to the scheme being voted down. Maybe they also need to see what price point is likely to be successful for a second attempt/offer from Pfizer stealing the company for chicken feed. I would think a second offer in the mid to higher half of the IE valuation range is a possibility if the no vote goes through.

Not long until we know.

Vote no!

RAP Price at posting: 11.5¢ Sentiment: Hold Disclosure: Held
18 Upvote

0 Great analysis

Reply

Top Stories

THL

Tourism Holdings says Liberation Day tariffs smashed US RV demand

KGD

Kula picks up unexplored niobium play in Malawi, with surface samples logged

Trump chides Powell as Goldman call for calm. The RBA must be nervous

NMG

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

SPONSORED BY